Home / Treatments / Tesamorelin / Online
This article is educational and does not replace medical advice. Prescription medication requires review by a licensed clinician and, when appropriate, a valid prescription. Compounded medications are not FDA-approved, and the FDA does not verify their safety, effectiveness or quality before marketing. Treatment eligibility is an individual clinical decision.
Released: ·Last reviewed: ·Prices verified October 15, 2026·Methodology v4.1

Buying Tesamorelin online: how to tell a real programme from a storefront

Direct answer

Tesamorelin is a GHRH analogue and — importantly — one of the few peptides in this category that is <b>genuinely FDA-approved</b>, though for a narrow indication: the reduction of excess abdominal fat in adults with HIV-associated lipodystrophy. It is marketed as Egrifta. Everything else it is sold for is off-label.

Buying Tesamorelin online — what to look for

Tesamorelin (Egrifta) is FDA-approved, for one specific indication: excess visceral abdominal fat in HIV-infected patients with lipodystrophy. This is the strongest regulatory position of any peptide on this site, and it deserves to be stated clearly.

It also deserves to be qualified. The approval does not extend to general weight loss, body composition in healthy adults, anti-ageing or athletic performance. And compounded tesamorelin — which is what most telehealth and longevity clinics dispense — is not the FDA-approved product and carries none of that regulatory assurance.

The four things a legitimate programme hasA legitimate telehealth programme has four things: a named prescribing clinician, a real medical evaluation rather than a form that approves everyone, a named pharmacy you can look up in a state board database, and no 'research use only' language anywhere on the site. 'Research use only' or 'not for human consumption' means the seller is not operating as a pharmacy at all, and nothing about the product's identity, purity or sterility has been established. Walk away.

Questions to ask about the pharmacy

The pharmacy matters more than the telehealth brand on the front of the website. The telehealth company arranges the consultation; the pharmacy makes the medicine you inject.

  1. Which specific pharmacy will fill my prescription? Not "our network" — the name of the facility.
  2. Is it a 503A state-licensed pharmacy or a 503B FDA-registered outsourcing facility? These are different regulatory categories with different oversight, and a company can use both for different products.
  3. In which state is it licensed, and can I look up the licence? State boards of pharmacy publish licensee databases.
  4. What is the exact substance, salt form and concentration? Get it in writing, and check the substance’s status on our peptide status table.
  5. Is the vial single-dose or multi-dose? A multi-dose vial requires you to measure each dose yourself, which is the most common source of the dosing errors behind reported adverse events.
  6. Will you provide a certificate of analysis?
  7. Has the pharmacy received any FDA warning letter or state board action?

A provider that answers all seven in writing is demonstrating something real. A provider that will not name its pharmacy has given you an answer, whether it intended to or not.

Frequently asked questions

What does Tesamorelin cost through telehealth?

We have not verified a market price. On October 15, 2026, the Egrifta WR website published no list price, describing co-pay and patient assistance programs instead, and Oak Longevity priced tesamorelin only after an assessment. Ask for the total cost in writing, and ask whether you will get Egrifta WR or a compounded product.

Is Tesamorelin FDA-approved?

Yes, for one use. Egrifta WR is approved to reduce excess abdominal fat in HIV-infected adults with lipodystrophy, and its label says it is not indicated for weight-loss management. Compounded tesamorelin is not the approved product, and other uses are off-label.

Does Tesamorelin work?

FDA approved Egrifta WR on clinical trial evidence in adults with HIV and lipodystrophy. We found no comparable trials for general fat loss, anti-ageing or performance in other people, and approval for one condition is not evidence for another.

Sources

  1. U.S. Food and Drug Administration — approved labels and compounding guidance for this molecule.
  2. PubMed / NIH — indexed human clinical literature.
  3. ClinicalTrials.gov — registered trials, where they exist.
  4. Our source hierarchy and pricing-verification methodology.

Spotted an error? Submit a correction.

Researched ByDr. Parmis · Medical Researcher · Western University of Health Sciences

Medically Reviewed ByDr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)

Last medically reviewed: · This page is informational and does not constitute medical advice.